CD20 Antibody Development Service

CD20 antibodies acting with a few different mechanisms have been applied to destroy overactive B cells in a series of autoimmune diseases. Our company provides top-notch research services to help you to develop antibodies with high performance and purity, offering the necessary services and materials for the development of therapeutic antibodies for Autoimmune Diseases & Inflammation.

CD20 in Autoimmune Diseases & Inflammation

CD20 is a nonglycosylated phosphoprotein without any appointed ligands that located on the surface of B cells and is mainly expressed from B cells of various statuses. After B cells differentiate to form mature plasma cells, the expression of CD20 is diminished, thus limiting the off-target cellular toxicity of CD20-directed therapies. CD20 can bind with B cell receptor (BCR) complex to activate the BCR signaling that is crucial for directing B cell survival and differentiation. And CD20 also functions as a channel for calcium influx associated with B cells activation. These characteristics have led CD20 to be considered as a positive target to regulate the outcome of Autoimmune Diseases & Inflammation.

Fig.1 A schematic view of interacting partners of CD20 on cell membrane and mechanisms of CD20 gene (MS4A1) regulation in malignant B cells. (Pavlasova G., et al., 2020)

• CD20 Antibody Acting Through CDC
  Antibodies acting through the complement dependent cytotoxicity (CDC) mechanism reallocate CD20 into lipid rafts and stimulate the activation of canonical C1q cascade. Then the target cells are eliminated by complement-dependent cytotoxicity (CDC).

• CD20 Antibody Acting Through ADCC
  The Fc gamma receptor (FcγR) expressed from macrophages and natural killer cells interacts Fc with region of CD20 antibodies to trigger the release of granzyme B and other compounds to onset the antibody-dependent cell-mediated cytotoxicity (ADCC).

• CD20 Antibody Acting Through ADPC
  The phagocytic function of phagocytes is activated by signals through the interaction of FcγR and Fc. After the fusion with phagosome, the target cell is disintegrated by the antibody-dependent cell-mediated phagocytosis (ADCP).

• CD20 Antibody Acting Through ROS Dependent Death
  The antibodies of CD20 prompt the target cells to generate excessive reactive oxygen species (ROS), which result in the oxidative damage of DNA and proteins and ultimately triggers cell death.

In addition to the above mechanisms, CD20 antibodies can act by other mechanisms and show variable potency in cells from different autoimmune diseases. These mechanisms reflect the characteristics of CD20 molecules that make them favourable to bind to antibodies, leading to a very competitive market for the development of CD20 antibodies.

Our Services

The development of antibodies against CD20 has taken decades. The innovation in research and development technology has made this work more targeted and more efficient. Our company provides competent and promising antibodies development services for CD20 as the following workflow: 

Antigen Validation

CD20 signaling pathways

Antibody Generation

Antibody Optimization

Antibody Characterization

Antibody Production & Purification

Our advantages

With the professional service team, and closely following the first line information of antibody research and development, our company is devoted to providing precise and personalized services for the development of therapeutic antibodies to CD20. If you are interested in our services, please contact us for more detailed information. 

Reference

1. Pavlasova, Gabriela, and Marek Mraz. "The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy." Haematologica 105,6 (2020): 1494-1506.